|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM321103661 |
| 003 |
DE-627 |
| 005 |
20250228224922.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108684
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1070.xml
|
| 035 |
|
|
|a (DE-627)NLM321103661
|
| 035 |
|
|
|a (NLM)33549834
|
| 035 |
|
|
|a (PII)S1521-6616(21)00021-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Wei
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A novel intracellular nanobody against HPV16 E6 oncoprotein
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.06.2021
|
| 500 |
|
|
|a Date Revised 11.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Cervical cancer occurs as a result of the persistent infection of high-risk human papillomavirus (HPV). HPV16 oncoproteins E6 and E7 exert different and concerted pro-tumor actions in cell transformation and malignance maintenance in various m echanisms. Nanobody expressed as "intracellular antibodies" (intrabodies) can target intracellular antigens to hamper their function efficaciously and specifically. In this work, phage-display approach was employed to select the high affinity HPV16 E6-specific nanobody, nanobody Nb9 against HPV16 E6 was selected. Nb9 has high affinity (Kaff =6.3 × 108 M-) and can specifically bind endogenous HPV16 E6 protein in HPV16 positive CaSki and SiHa cells. In Nb9 overexpressed SiHa and CaSki cells, nucleus localization of HPV16 E6 was inhibited, p53 inactivation was prevented and increased apoptosis was observed. Moreover, tumor growth was inhibited in mouse xenograft model. Taken together, our results suggested that nanobody Nb9 could be a useful inhibitor for HPV16 E6 function and particularly appropriate for the treatment of HPV-associated disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Cervical cancer
|
| 650 |
|
4 |
|a E6
|
| 650 |
|
4 |
|a Human papillomavirus (HPV)
|
| 650 |
|
4 |
|a Nanobody (Nb)
|
| 650 |
|
4 |
|a VHH
|
| 650 |
|
7 |
|a E6 protein, Human papillomavirus type 16
|2 NLM
|
| 650 |
|
7 |
|a Oncogene Proteins, Viral
|2 NLM
|
| 650 |
|
7 |
|a Repressor Proteins
|2 NLM
|
| 650 |
|
7 |
|a Single-Domain Antibodies
|2 NLM
|
| 700 |
1 |
|
|a Shan, Haitao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Kunpeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Wenbin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Shufeng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 225(2021) vom: 01. Apr., Seite 108684
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:225
|g year:2021
|g day:01
|g month:04
|g pages:108684
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108684
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 225
|j 2021
|b 01
|c 04
|h 108684
|